Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTAPI 0
Description: ADAM-17 (TACE) and MMP inhibitor
Alternative Names: TNF-α processing inhibitor-0
Chemical Name: N-[(2R)-2-[2-(Hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-L-alaninamide
Purity: ≥95% (HPLC)
Biological Activity for TAPI 0
TAPI 0 is an ADAM-17 (TACE) and MMP inhibitor; attenuates TNF-α processing. Acts in concert with GM6001 (Cat. No. 2983) to inhibit Chlamydia trachomatis growth.
Technical Data for TAPI 0
| M. Wt | 456.54 |
| Formula | C24H32N4O5 |
| Storage | Store at -20°C |
| Purity | ≥95% (HPLC) |
| CAS Number | 163958-73-4 |
| PubChem ID | 3035404 |
| InChI Key | CRCPLBFLOSEABN-VBSNWNEZSA-N |
| Smiles | ONC(C[C@@H](CC(C)C)C(N[C@@H](CC1=CC(C=CC=C2)=C2C=C1)C(N[C@@H](C)C(N)=O)=O)=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for TAPI 0
| Solubility | Soluble to 10 mg/ml in DMSO |
Product Datasheets for TAPI 0
References for TAPI 0
References are publications that support the biological activity of the product.
Balakrishnan et al (2006) Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J.Biol.Chem. 281 16691 PMID: 16565079
Rzeniewicz et al (2015) L-selectin shedding is activated specifically within transmigrating pseudopods of monocytes to regulate cell polarity in vitro. Proc.Natl.Acad.Sci.USA. 112 E1461 PMID: 25775539
If you know of a relevant reference for TAPI 0, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TAPI 0, TAPI 0 supplier, TAPI0, ADAM17, metalloproteases, MMPs, metalloproteinases, inhibits, inhibitors, adams, TNFa, TNFα, converting, enzyme, TACE, TNF-a, processing, inhibitor-0, ADAMs, Matrix, Metalloprotease, 5523, Tocris Bioscience
Citations for TAPI 0
Citations are publications that use Tocris products.
Currently there are no citations for TAPI 0. Do you know of a great paper that uses TAPI 0 from Tocris? Please let us know.
Reviews for TAPI 0
Average Rating: 4 (Based on 1 Review.)
Have you used TAPI 0?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
In vitro cell treatment.
By
Anonymous on 01/04/2019
Assay Type: In Vitro
Species: Mouse
Cells were treated with 10 um TAPI-0 to study cell surface protein shedding
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Immunology Product Listing
A collection of over 190 products for immunology research, the guide includes research tools for the study of:
- Chemokine and Cytokine Signaling
- Chemotaxis
- Complement System
- Immune Cell Signaling
- Inflammation
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.